logo

Indian News

Share

pharma-052317_12nov19.jpg Today's Daily Dose brings you news about the disappointing TreeTopp trial results of ASLAN Pharma; better-than-expected financial results of Castle Biosciences; positive topline results from Kadmon's planned interim analysis of its ROCKstar trial; updated results from NextCure's phase I/II trial with NC318.

pharmaup-nov11.jpg The following are some of today's top gainers in the healthcare sector.

confetrence-nov11.jpg The announcement of clinical trial results is a major market-moving event for pharma/biotech stocks. Listed below are some of the pharma/biotech stocks to watch out for today and tomorrow.

pharma-041017_10nov19.jpg Today's Daily Dose brings you news about Alnylam's new positive efficacy results from its ongoing phase II open-label extension (OLE) study of Lumasiran for the treatment of primary hyperoxaluria type; Five Prime's initial safety data from its phase I clinical trial of FPT155 in patients with advanced solid tumors and Lipocine's much-awaited catalyst.

moodys-050517_08nov19.jpg Moody's Investors Service downgraded India's rating outlook to 'negative' from 'stable', citing rising risks that economic growth would be materially lower than in the past as the government struggles to rein in the fiscal deficit. The country's sovereign ratings were affirmed at 'Baa2', the second lowest investment grade.

Follow RTT
>